-
Kantai Bio's first-half net profit fell 9.84% year-on-year to raise 3 billion yuan
Time of Update: 2021-03-04
According to Pacific Securities analysis, Kantai bio-research and development of the five seedlings are expected to be listed in 2021-2022; ( Sina Pharmaceutical News )
-
Where is the hard time for China's pharmaceutical industry in 2019 when old dividends are exhausted?
Time of Update: 2021-03-04
there are many signs that the pharmaceutical industry may really be harder than it's been before in 2020. It is not only a symbolic beginning of the new decade, is the old dividend to eat up the year
-
China Resources Pharmaceutical Holdings indirectly holds a 30% stake in Jiang Traditional Chinese Medicine
Time of Update: 2021-03-04
20, Jiang Traditional Chinese Pharmaceuticals announced that China Resources Pharmaceuticals Holdings intends to take a 51% stake in Jiang zhong group and become its controlling shareholder. China Re
-
Murray forecasts half-year results Endoscopes or new growth points
Time of Update: 2021-03-04
, life information and support business accounted for 38% of Myer's total revenue, of which the monitor has become the first domestic market share.
2017, Myer, Philips and GE's monitors had a domestic market share of 64.8%, 17.7% and 3.8%, respectively, according to the China Medical Device Association.
-
Medical imaging diagnostic equipment field: continuous improvement is worth looking forward to
Time of Update: 2021-03-04
Among them, the rapid development of domestic PET-CT/MRI, import substitution continued to improve, domestic magnetically controlled capsule gastroscope leading foreign enterprises approved for listing in China, in the medical examination and hospital market penetration has a greater room for improvement, domestic in-vascular ultrasound (IVUS) equipment has entered the special examination procedures for innovative medical devices, it is worth looking forward to.
-
"Sky-price ticket" limited effect of life-saving drugs cheap medicine cut off the solution
Time of Update: 2021-03-03
He Xiangling, director of the Children's Hematology Department of Children's Medical Center of Hunan Provincial People's Hospital, said that in Hunan, children's anti-cancer drugs, including tablets, dakabazine and so on, have also been cut off several times, and the families of the children have to buy drugs everywhere, online for medicines, on the one hand, the quality of drugs is difficult to ensure, on the other hand, drug prices have also increased a lot.
-
Six pharmaceutical mergers and acquisitions this month Fosun built a $1 billion API base
Time of Update: 2021-03-03
The state-owned enterprises 2 billion real control of Hainan Hai Medicine recently, Hainan Hai Medicine announcement shows that: November 16, 2018, Hainan Hai Medicine received the company's controlling shareholder Shenzhen Southern Tongzheng Investment "notice letter." in order to promote the long-term sustainable development of the company, Mr. Liu Shicheng, the de facto controller of Southern Tongzheng Company, and his spouse, Ms. Qiu Xiaowei, signed the Cooperation Framework Agreement with Emerging Inter-China Pharmaceutical Holdings (Party A).
-
Jiangsu pharmaceutical enterprises three giants hold the group to dominate the 10 billion market!
Time of Update: 2021-03-03
Enhua's half-year revenue broke 2 billion, 4 major psychostated drugs consistency evaluation in the process of Table 1: 2019 first half of Enhua Pharmaceuticals' main products performance (Source: Listed Companies Semi-Annual Report) According to half-yearly report, Enhua Pharmaceuticals' operating income in the first half of 2019 was RMB2,097 million, up 12.41% YoY, and net profit was RMB322 million, up 22.87% YoY.
-
Changchun High-new premium 12.76 times to buy a 29.5% stake in Kinsey Pharmaceuticals
Time of Update: 2021-03-03
3/6/2019, Changchun Gaoxin announced that it intends to issue shares and convertible bonds to Jinlei and Lin Tianhai for 174.49 yuan per share to purchase 30% of its shares in Jinsai Pharmaceuticals.
At the same time, Changchun Gaoxin intends to raise matching funds by non-publicly issuing shares or convertible bonds.
-
Yi Heng Health is listed on NASDAQ
Time of Update: 2021-03-03
According to the data disclosed in the prospecto, Yiheng Health's total revenue for 2018 was $199 million, up 103.1% YoY, and revenue for the first half of 2019 was $151 million, up 112.7% YoY.
In the first half of 2019, net profit increased 131%
-
The decline in research and development power of pharmaceutical giants has slowed the growth rate of the number of research and development enterprises
Time of Update: 2021-02-28
In 2018, when Big Mac mergers and acquisitions activity declined, followed by a decline in the number of products under development, only six of top25 pharmaceutical companies are studying an unprecedented increase in the number of drugs.
-
Antitrust investigation terminates Hainan Haipharma's $2.1 billion acquisition of Qili Pharmaceuticals
Time of Update: 2021-02-28
Anti-monopoly investigation terminated, today resumed trading, Hainan Hai Pharmaceuticals acquisition of Qili Pharmaceuticals has made new progress Yesterday, Hainan Hai Pharmaceutical Co., Ltd. (here
-
Domestic energy tycoons are going to cross the border into the medical industry
Time of Update: 2021-02-28
("Shanghai Electric") officially announced the establishment of a $1.6 billion medical device merger and acquisition fund with established private equity firm Yongyong.
-
Merck Pharma holding hands with Ali Health Path-to-Road Pharmaceutical e-commerce
Time of Update: 2021-02-28
On June 20, Merck Pharma and Ali Health signed a strategic partnership framework agreement to create patient-centric digital health services that bring more medical and health services to patients and
-
Half a year later, the three pharmaceutical companies will finally be sold
Time of Update: 2021-02-28
Under financial pressure, there is a view that The divestiture of the three subsidiaries, including Shanghai Huato, Shanxi Pude are in previous years mergers and acquisitions, revenue, assets accounted for a higher proportion of listed companies, the acquisition involved nearly 3 billion, Yuheng this "suffering" to sell it, perhaps another reason is to achieve rapid withdrawal of funds.
-
Foreign giants monopolize the upper reaches of the gene sequencing industry chain And domestic manufacturers are trying to break the ice
Time of Update: 2021-02-28
third type of research and development is completely independent property rights, but also in the true sense of localization, such as the Shenzhen Hanhai gene dedicated to three generations of sequencer technology.
-
Xinda Bio's two monoclonal antibodies were approved clinically at the same time
Time of Update: 2021-02-28
Xinda Biopharmaceutical Co., Ltd. announced that the company developed injection recombinant all-human source anti-OX40 monoclonal antibody (research and development code IBI101) and recombinant all-human source anti-RANKL monoclonal antibody injection (research and development code IBI307) at the same time obtained the National Drug Administration issued clinical trial approval.
-
Ruikang's device business is selling 7 billion yuan a year, and the president has revealed his next steps
Time of Update: 2021-02-28
As one of the few pharmaceutical circulation enterprises in China that have completed the national layout, Ruikang Pharmaceutical founder and president Zhang Renhua recently told China Securities News in an exclusive interview that the company will further improve the business network and product line layout on the basis of the existing 31 provincial platforms, and grow into a national platform, data, scientific and technological medical circulation service enterprises.
-
Chinese medicine injection limit companies under pressure China Resources 39 and other products sales decline
Time of Update: 2021-02-28
Not unique, Lizhu Group recently in the investor relations activity record table, in the past two years, many Chinese medicine injections have been affected by medical reform policies, tender price reduction, especially from the fourth quarter of 2017, superimposed on the new version of health insurance and drug proportion pressure, the injection in some hospitals under greater pressure, in the first quarter of 2018, the variety of income of 24.7% decline.
-
Hengrui Pharmaceuticals' share price rose to become the first pharmaceutical company to break 300 billion A-shares
Time of Update: 2021-02-28
2017, Hengrui Pharmaceuticals revenue of 13.836 billion yuan, net profit of 3.217 billion yuan, in the 18 years of listing, respectively, increased about 28 times, 48 times, while the share price increased by more than 250 times, far higher than the performance growth.
